Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Cancer Hospital & Institute
About this trial
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
Eligibility criteria
Qualifiers
Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)
No prior systemic therapy for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed.
BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy
At least one measurable lesion per RECIST v1.1
Disqualifiers
Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously
Moderate-to-severe ascites with clinical symptoms
History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
Trial design
Treatments tested in this trial
- Adebrelimab plus Apatinib
- Adebrelimab plus Bevacizumab
- Camrelizumab plus Apatinib
Treatment groups
111 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov